MDM4 and cancer: ACIN1 and SYNE2 showed a combined effect with ESR2 on either OS or DFS in 9 out of 17 cancer types, TNFRSF13C showed a combined effect with ESR2 in 8 cancer types, and MDM4 showed a combined effect with ESR2 in 7 cancer types.